HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshihide Asano Selected Research

Systemic Scleroderma (Systemic Sclerosis)

1/2022Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.
1/2022The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.
1/2022Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
12/2021Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model.
8/2021Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis.
1/2021Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia.
1/2021Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis.
1/2021Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma.
11/2020Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis.
9/2020Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshihide Asano Research Topics

Disease

96Systemic Scleroderma (Systemic Sclerosis)
01/2022 - 02/2003
43Fibrosis (Cirrhosis)
01/2022 - 04/2004
26Inflammation (Inflammations)
02/2021 - 01/2012
23Interstitial Lung Diseases (Interstitial Lung Disease)
01/2022 - 04/2011
19Psoriasis (Pustulosis Palmaris et Plantaris)
05/2021 - 02/2012
15Neoplasms (Cancer)
02/2021 - 03/2011
15Sclerosis
01/2021 - 06/2011
12Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
12/2018 - 12/2011
10Pulmonary Fibrosis (Fibrosing Alveolitis)
01/2022 - 02/2003
10digital ulcers
11/2020 - 10/2011
8Autoimmune Diseases (Autoimmune Disease)
12/2021 - 08/2010
8Pulmonary Arterial Hypertension
01/2020 - 01/2010
8Atopic Dermatitis (Atopic Eczema)
12/2018 - 10/2011
6Dermatomyositis (Dermatopolymyositis)
01/2013 - 07/2002
5Skin Diseases (Skin Disease)
01/2022 - 05/2006
5Dermatitis
05/2021 - 07/2015
5Localized Scleroderma (Morphea)
08/2020 - 06/2004
5Leukemia
02/2018 - 04/2010
5Systemic Lupus Erythematosus (Libman-Sacks Disease)
10/2014 - 02/2003
4Telangiectasis (Telangiectasia)
08/2021 - 01/2016
4Mycosis Fungoides
01/2020 - 03/2013
4Ulcerative Colitis
12/2019 - 02/2011
4Vascular System Injuries
01/2018 - 10/2011
4Disease Progression
01/2017 - 06/2011
3Rheumatoid Arthritis
05/2022 - 06/2011
3Pruritus (Itching)
01/2018 - 03/2013
3Pathologic Processes
01/2017 - 05/2015
3Wounds and Injuries (Trauma)
12/2015 - 09/2012
3Diffuse Scleroderma (Progressive Systemic Sclerosis)
06/2014 - 10/2011
2Pathologic Constriction (Stenosis)
06/2021 - 10/2011
2Paraproteinemias (Monoclonal Gammopathy)
06/2021 - 11/2007
2Arthralgia (Joint Pain)
01/2021 - 06/2004
2Cicatrix (Scar)
01/2018 - 06/2016
2Pathologic Neovascularization
01/2015 - 05/2014
2Infections
08/2014 - 07/2006

Drug/Important Bio-Agent (IBA)

16Bleomycin (Blenoxane)FDA LinkGeneric
01/2022 - 08/2010
15Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2019 - 05/2006
12Transcription Factors (Transcription Factor)IBA
11/2018 - 01/2010
11EnzymesIBA
01/2015 - 02/2003
10CytokinesIBA
01/2022 - 01/2010
9ChemokinesIBA
01/2022 - 04/2012
9Interleukin-17 (Interleukin 17)IBA
11/2020 - 11/2011
9AutoantibodiesIBA
01/2020 - 07/2002
8Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2012
8Messenger RNA (mRNA)IBA
02/2021 - 05/2013
8indium-bleomycinIBA
01/2018 - 04/2014
8ImmunosorbentsIBA
01/2015 - 02/2003
7CollagenIBA
01/2022 - 10/2003
7Interleukin-6 (Interleukin 6)IBA
01/2022 - 10/2011
7AntigensIBA
12/2021 - 07/2002
7Imiquimod (Aldara)FDA LinkGeneric
05/2021 - 02/2013
7Pharmaceutical PreparationsIBA
12/2020 - 08/2008
7AdiponectinIBA
01/2019 - 09/2012
7AntibodiesIBA
11/2014 - 07/2002
6Transforming Growth Factors (Transforming Growth Factor)IBA
01/2022 - 01/2010
6Interleukin-10 (Interleukin 10)IBA
02/2021 - 11/2011
6AdipokinesIBA
01/2017 - 05/2013
5Rituximab (Mabthera)FDA Link
01/2022 - 05/2014
5Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022 - 08/2010
5Type I DNA Topoisomerases (Topoisomerase I)IBA
12/2021 - 11/2011
5InterleukinsIBA
10/2021 - 08/2017
5LigandsIBA
05/2021 - 01/2011
5Indicators and Reagents (Reagents)IBA
11/2017 - 02/2003
5Bosentan (Tracleer)FDA Link
01/2017 - 08/2011
5anti-scl-70 autoantibodiesIBA
01/2017 - 08/2010
4Carbon MonoxideIBA
11/2020 - 02/2003
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2018 - 12/2015
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2018 - 02/2005
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 02/2012
4Nicotinamide PhosphoribosyltransferaseIBA
08/2014 - 05/2013
3Chemotactic FactorsIBA
02/2021 - 05/2014
3Biomarkers (Surrogate Marker)IBA
01/2021 - 02/2017
3Biological ProductsIBA
09/2020 - 06/2017
3anticentromere antibodyIBA
08/2020 - 04/2005
3RNA Polymerase IIIIBA
07/2020 - 05/2015
3Adalimumab (Humira)FDA Link
12/2019 - 10/2015
3SteroidsIBA
11/2018 - 10/2012
3Angiopoietin-2IBA
02/2017 - 09/2013
3Cell Adhesion MoleculesIBA
09/2015 - 12/2013
3Imatinib Mesylate (Gleevec)FDA Link
02/2012 - 08/2008
2Tacrolimus (Prograf)FDA LinkGeneric
01/2022 - 06/2011
2AutoantigensIBA
12/2021 - 02/2012
2Immunoglobulin M (IgM)IBA
06/2021 - 07/2006
2Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA
11/2020 - 07/2020
2Peptide Hydrolases (Proteases)FDA Link
09/2020 - 04/2016
2Hydroxyproline (4 Hydroxyproline)IBA
02/2020 - 01/2015
2ProgranulinsIBA
11/2018 - 12/2015
2Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
11/2018 - 12/2015
2Interleukin-2 Receptors (IL 2 Receptor)IBA
04/2018 - 03/2013
2Heparin (Liquaemin)FDA LinkGeneric
02/2018 - 06/2015
2Immunoglobulin G (IgG)IBA
01/2018 - 10/2005
2Adiponectin ReceptorsIBA
01/2018 - 01/2017
2tocilizumab (atlizumab)FDA Link
08/2017 - 01/2017
2DNA (Deoxyribonucleic Acid)IBA
01/2017 - 04/2014
2trioctyl phosphine oxide (TOPO)IBA
01/2017 - 11/2011
2Interleukin-4 (Interleukin 4)IBA
02/2016 - 04/2012
2Interleukin-13IBA
02/2016 - 03/2006
2Antimicrobial PeptidesIBA
08/2014 - 05/2013

Therapy/Procedure

20Therapeutics
05/2022 - 05/2006
2Phototherapy (Light Therapy)
12/2017 - 01/2016